

1 Whole-Blood DNA Methylation Analysis Reveals Respiratory Environmental 2 Traits Involved in COVID-19 Severity Following SARS-CoV-2 Infection

3 Guillermo Barturen¹, Elena Carnero-Montoro¹, Manuel Martínez-Bueno¹, Silvia Rojo-Rello², Beatriz
4 Sobrino³, Clara Alcántara-Domínguez⁴, David Bernardo^{5,6} and Marta E. Alarcón-Riquelme^{1,7}

5 ¹GENYO. Center for Genomics and Oncological Research Pfizer/University of Granada/Andalusian
6 Regional Government. Granada, Spain.

7 ²Servicio de Microbiología e Inmunología. Hospital Clínico Universitario de Valladolid. Valladolid,
8 Spain.

9 ³Servicio de Enfermedades Infecciosas. Hospital Regional de Málaga. Málaga, Spain.

10 ⁴Lorgen G.P., S.L., Business Innovation Center - BIC/CEEL, Technological Area of Health Science,
11 Granada, Spain.

12 ⁵Mucosal Immunology Lab. Unidad de Excelencia Instituto de Biomedicina y Genética Molecular de
13 Valladolid (IBGM, Universidad de Valladolid-CSIC). Valladolid, Spain.

14 ⁶Centro de Investigaciones Biomédicas en Red de Enfermedades Hepáticas y Digestivas
15 (CIBERehd). Madrid, Spain.

16 ⁷Unit of Inflammatory Chronic Diseases, Institute of Environmental Medicine, Karolinska Institutet,
17 Stockholm, Sweden.

18 Correspondence: Guillermo Barturen and Marta E. Alarcón-Riquelme: GENYO. Center for
19 Genomics and Oncological Research Pfizer/University of Granada/Andalusian Regional
20 Government, Av de la Ilustración 114, Parque Tecnológico de la Salud, 18016, Granada, Spain.
21 guillermo.barturen@genyo.es and marta.alarcon@genyo.es

22 Abstract

23 SARS-CoV-2 causes a severe inflammatory syndrome (COVID-19) leading, in many cases, to
24 bilateral pneumonia, severe dyspnea and in ~5% of these, death. DNA methylation is known to
25 play an important role in the regulation of the immune processes behind COVID-19 progression,
26 however it has not been studied in depth, yet. In this study, we aim to evaluate the implication of
27 DNA methylation in COVID-19 progression by means of a genome-wide DNA methylation analysis
28 combined with DNA genotyping.

29 The results reveal the existence of epigenomic regulation of functional pathways associated with
30 COVID-19 progression and mediated by genetic loci. We found an environmental trait-related

31 signature that discriminates mild from severe cases, and regulates IL-6 expression via the
32 transcription factor CEBP. The analyses suggest that an interaction between environmental
33 contribution, genetics and epigenetics might be playing a role in triggering the cytokine storm
34 described in the most severe cases.

35 Keywords

36 EWAS, SARS-CoV-2, COVID-19, Epigenomics, mQTLs, Autoimmunity

37 Introduction

38 SARS-CoV-2 virus infection has affected millions of people during the last year worldwide. Most
39 infected SARS-CoV-2 individuals remain asymptomatic or with mild symptoms that do not require
40 hospitalization (~81%), while in other, the virus cause a severe inflammatory syndrome called
41 COVID-19 that primarily affects the lungs leading, in many cases, to bilateral pneumonia, severe
42 dyspnea and in ~5% of the cases, death^{1,2}.

43 Several genetics, transcriptomics, and proteomics molecular studies have been performed to date,
44 disentangling important pathogenic molecular mechanisms of the disease (3-14). In summary,
45 SARS-CoV-2 infects the cells expressing surface receptors ACE2 and TMPRSS2³ causing cell damage
46 due to its replication and release from the host cell. Then, this process triggers in the surrounding
47 cells the production of pro-inflammatory cytokines and chemokines (including IL-1, IL-6, IL-8, IL-10,
48 TNF and interferon inducible molecules, among others), which establish a pro-inflammatory
49 response mediated by the accumulation of specific immune cells⁴. In severe cases, an
50 overexpression of cytokines is produced in lung tissues, known as cytokine storm, thus provoking
51 an over-response of the immune system and causing tissue damage. In the most critical cases, the
52 cytokine storm is spread to other organs leading to multi-organ failure and death. Currently, the
53 molecular mechanisms and the pathophysiology behind COVID-19 progression are largely studied

54 and well established, but it is still unclear what makes some individuals develop the severe illness.
55 In this sense, underlying genetic variation⁵ and different comorbidities have been identified as risk
56 factors, such as diabetes, hypertension, chronic lung disease or even neurological disorders^{6,7}. Also
57 life style habits, that might be causing the previous conditions have been also related to COVID-19
58 illness as obesity or smoking, as well as age, gender or ethnicity^{8,9}. However, it is unclear how
59 these comorbidities, environmental and demographic conditions together with genetics,
60 predispose and regulate the molecular mechanisms behind COVID-19 severity.

61 In order to shed light into the molecular relationship between risk factors and the regulation of
62 the mechanisms behind the COVID-19 severity, here we present a DNA methylation EWAS
63 (epigenome wide association analysis) combined with DNA genotyping for 473 and 101 SARS-CoV-
64 2 lab positive and negative tested individuals recruited in two independent clinical centers. In
65 addition to the study of the epigenetic regulation of COVID-19 pathogenic mechanisms, the DNA
66 methylation changes associated with COVID-19 progression, and its genetic regulation were put in
67 context by comparing the results with DNA methylation changes occurring in systemic
68 autoimmune diseases (SADs), and with GWAS (genome wide association analysis) and EWAS
69 catalogs that collect multiple traits described as potential COVID-19 severity risk factors.

70 Results

71 *COVID-19 severity relates to impaired blood cell proportions and epigenetic activation of the*

72 *innate immune response*

73 Main blood cell type proportions were deconvoluted from the methylomes, showing a significant

74 increase of neutrophil proportions associated with severity of the disease (Figure 1A and

75 Supplementary Figures 1A and 1B). This imbalanced neutrophil proportion has been already

76 shown to be related to COVID-19 severity progression¹⁰, and proposed as an early prognostic

77 signature¹. Besides cell proportion differences, significant differences in age and gender between

78 groups were found in the discovery dataset (Wilcoxon test p -value < 0.05 for age in severe group

79 compared to mild and negative individuals, and Fisher's exact test p -value < 0.05 for gender

80 proportion in severe group compared with mild group). Methylation plates did not show batch

81 bias, being the largest bias between cohorts (Supplementary figures 1B and 1D). Based on these

82 results, differential methylation analyses included as covariates: gender, age and the six major

83 deconvoluted cell proportions.

84 Differential analyses were performed by pairs and longitudinally, after translating groups' severity

85 to a numerical scale (severity analysis, hereafter). We identified 530 CpGs differentially

86 methylated in at least one regression model, and replicated in the validation cohort. Out of these,

87 43 DMCs were found in the severe-negative comparison, 347 in the mild-negative, 20 in severe-

88 mild and 257 in the severity analysis (significant DMCs can be consulted in the Supplementary

89 Files). We observed high degree of sharing between DMCs obtained in different comparisons

90 (Figure 1B), except for the severe-mild DMCs which did not overlap with any of the other analyses

91 results'. These specific DMCs from the severe-mild analysis were hypermethylated in the severe

92 condition. Overall, 24 DMCs, annotated into 17 different genes were shared between severe-

93 negative, mild-negative and with the severity analyses (Figure 1B and 1C), which give a general

94 idea of the epigenetic contribution to the progression of COVID-19. Most of the shared signatures
95 are related to the activation of the viral defense type I interferon inducible genes (OAS1-OAS2
96 hypermethylated and PARP9-DTX3L, IFIT3, IRF7, TRIM22, MX1 hypomethylated), the
97 hyperactivation of B and T lymphocytes (CD38, EPSTI1, LAT hypomethylated), and others, as EDC3,
98 known to interact with ACE2 ¹¹.

99 DMCs localization enrichment analysis showed that hypermethylated changes related to SARS-
100 CoV-2 infection are more prone to occur outside CGIs and in introns and in enhancers for the
101 hypomethylated sites (Supplementary Figure 2A). These genomic regions are known to be hot-
102 spots of DNA methylation changes ¹². However, most of the DMCs found in these analyses
103 colocalize around the TSS (Transcription Start Site) and/or in the 5'-UTR of the nearest gene
104 (Supplementary Figure 2B), due to the EPIC array probe selection. This probe's preferential
105 location facilitates the interpretation of the results, as hypermethylation and hypomethylation in
106 5'-end regions of the genes is directly related to the inactivation and activation of gene expression,
107 respectively ¹³.

108 *COVID19 disease DNA methylation changes in neutrophils, B-lymphocytes and CD8+ T-*
109 *lymphocytes regulate autoimmune and viral defense related functional pathways*

110 Functional enrichment analyses based on *Reactome pathway database* was performed taking into
111 consideration the groups compared and the direction of the effects. An enrichment of
112 hypomethylated signals at interferon-inducible genes, herein called IFN signature, and enrichment
113 of hypermethylated signals at genes involved in FCGR phagocytosis and CD209 signaling (DC-SIGN)
114 was observed when positive SARS-CoV-2 are compared to negative SARS-CoV-2 individuals (Figure
115 2A). The activation of IFN signature genes is related with an active viral infection and in particular
116 with SARS-Cov-2 infection ¹⁰. However, at DNA methylation level the impaired interferon response

117 between mild and severe cases found at the transcriptional level ¹⁴ cannot be observed
118 (Supplementary Figure 3). This suggests that the exhaustion of the interferon signature might be
119 controlled at a different regulatory level.

120 We performed interaction analysis between deconvoluted cell proportions and severity groups to
121 identify which blood cell type is contributing to the epigenetic signatures. Our results suggest that
122 interferon associated hypomethylation changes were mainly due to neutrophils and CD8+ T-
123 lymphocytes (Figure 2B), while hypermethylation changes are primarily related to B-lymphocytes
124 (Figure 2B) which in turn, might be related with the inactivation of CD209 signaling (Figure 2A).
125 CD8+ T-lymphocytes also showed a number of significant hypermethylated interactions (Figure 2B)
126 that may be related with the inactivation of FCGR3A phagocytosis-related genes in these cells
127 (Figure 2A). Lastly, in the severe-mild analysis, methylation changes of the PIP3 activated AKT
128 signaling pathway differentiate severe from mild COVID-19 patients (Figure 2A). Genes related
129 with this pathway are hypermethylated in severe cases compared with mild COVID-19 cases, being
130 CD8+ T-lymphocytes the major contributors to these changes (Figure 2B).

131 Finally, enrichment analyses were performed to assess to which other phenotypes or diseases the
132 COVID-19 DMCs had been associated. For that, we used the information gathered in the *EWAS*
133 *Atlas catalog* ¹⁵. Except for severe-mild DMCs, the other 3 comparisons showed DNA methylation
134 changes in CpGs that were previously associated with different autoimmune conditions, allergy
135 conditions, and an asthma related trait (as fractional exhaled nitric oxide test), but also with
136 differential respiratory related environmental exposures (air pollution and polybrominated
137 biphenyl exposure) and/or comorbidities that reflect lifestyle habits as body mass index, smoking
138 or alcohol consumption (Figure 2C).

139 *Respiratory environmental related epigenetic changes differentiate severe and mild COVID-*
140 *19 patients and mild COVID-19 cases from systemic autoimmune disorders*

141 Significant DMCs from all the differential analyses performed were clustered together based on
142 their methylation profile grouped by COVID-19 severity and divided into the two recruited cohorts
143 (Figure 3A). Hierarchical clustering reveals that, aside from the significant values obtained in the
144 linear regression models, not all trends of DMCs methylation changes are exactly replicated in
145 both cohorts. Thus, 4 DMC modules were obtained based on the hierarchical clustering where
146 DNA methylation changes were stable: S.Ho, composed by CpGs with a hypomethylation profile
147 along COVID-19 severity; S.He, characterized by a hypermethylation profile along COVID-19
148 severity; M.Ho, in which hypomethylation events are observed in mild as compared with severe
149 cases; and M.He, in which hypermethylation occurs in mild as compared with severe cases.

150 In summary, *Reactome* pathway enrichment analysis done on the 4 modules (Figure 3B) replicated
151 the previous enrichments found for the DMCs grouped in the linear regression analysis (Figure
152 2A). Interestingly, a new additional pathway appeared to be enriched in the S.He module, related
153 with potential therapeutics for SARS, which suggests that several of the proposed therapeutic
154 targets for SARS infection are based on the activation of hypermethylated molecular pathways
155 during the course of the COVID-19 disease. In order to validate the activation or inactivation of the
156 enriched pathways revealed by means of the DNA methylation changes, *Reactome* pathways
157 activity was estimated based on single-cell RNA-Seq information from publicly available analyses
158 ^{16,17}. The analysis was focused on the cell-types that mostly contribute to the DNA methylation
159 changes: CD8+ T-lymphocytes, B-lymphocytes and neutrophils, as revealed from the interaction
160 results (Figure 2B). In general, molecular pathway activities follow the DNA methylation changes at
161 early sampling time points, which correspond to our recruited cohorts. This is, that pathways that
162 show hypomethylation in certain group(s) of individuals coincide with a higher transcriptome

163 activity compared with the hypermethylated groups, at least in the cell-types in which the change
164 has been predicted to be occurring (Supplementary Figure 4). For example, the FCGR3A
165 phagocytosis pathway (enriched in S.He module) activity is decreased with the severity of the
166 disease in CD8+ T-lymphocytes, while the interferon signaling (enriched in S.Ho module) activity is
167 increased with the severity. Certainly, at the transcriptome level, the interferon exhaustion
168 signature associated with severe cases, not previously seen at the DNA methylation level
169 (Supplementary Figure 3), can be appreciated for B-lymphocytes and CD8+ T-lymphocytes.

170 On the other hand, *EWAS Atlas catalog* enrichments were performed by modules, revealing that
171 autoimmune and asthma related traits are mostly enriched in S.Ho and S.He modules, while the
172 differential respiratory environmental related traits were mostly enriched in the M.He module.
173 This M.He module differentiates severe and mild COVID-19 cases, suggesting an important
174 contribution of the respiratory environmental exposure to the progression of COVID-19 disease, at
175 least at the DNA methylation level.

176 TFBS motif analysis reveals specific TFBS motifs enriched for the different modules (Figure 3D).
177 S.Ho module was mainly enriched in interferon regulatory TFBSs, in line with the *Reactome*
178 pathway enrichment results, and among the other results stands out the enrichment of the CEBP
179 motif in M.He module. CEBP is a transcription factor related with the inflammatory immune
180 response by cooperating with and stimulating the transcription of different pro-inflammatory
181 cytokines¹⁸, among others, IL-6.

182 Given the potential relationship of COVID-19 affected molecular pathways and autoimmune
183 disorders, DNA methylation profiles were compared between COVID-19 and the PRECISESADS
184 collection¹⁹, which includes DNA methylation information from seven SADs (Figure 3E). Both,
185 severe and mild related DNA methylation changes correlate with systemic autoimmune disorders

186 for S.He module, with a slightly higher intensity in severe COVID-19 patients. S.Ho module
187 correlations are also significantly positive, except for RA and SSc comparison with mild cases,
188 which present no significant correlations. RA and SSc patients are known not to be frequently
189 expressing the IFN signature, enriched in S.Ho module²⁰. Thus, this result might be related with
190 the presence of two signatures contributing to this module, one related with the interferon, which
191 highly correlates with most interferon related SADs, and another one that correlates between
192 severe, RA and SSc. In order to further investigate the differential correlation between SADs in this
193 particular module, strongest hypomethylated CpGs in interferon related SADs and COVID patients
194 ($\log_{FC} < -0.25$) corresponding with IFN signature genes, were removed from the correlation
195 analyses (annotated in TRIM22-TRIM5, PARP9-DTXL3, RUNX1, IFIT3, IRF7, EPSTI1, MX1 and ADAR
196 genes). The correlation without these CpGs shows a dramatic reduction for interferon related
197 SADs, while RA and SSc correlations with severe cases are preserved (Supplementary Figure 5).
198 This means that the remaining CpGs (annotated in genes as CCDC61, CD38, FAM38A, LAT, TREX1
199 or NFAT5, among others) differentially contribute to COVID19 progression similarities with SADs,
200 some of them regulating the activation and differentiation of T and B lymphocytes. On the other
201 hand, M.He module shows a strong correlation for severe and a strong anti-correlation with mild
202 cases, thus differentiating mild cases from SADs. Lastly, M.Ho correlation results do not show
203 significant correlation values.

204 *DNA methylation changes that differentiate mild and severe COVID19 cases show low*
205 *genetic contribution and mQTLs enriched in SNPs associated with environmental traits*

206 As the DNA methylation modules that mostly differentiate severe and mild cases (M.He) were
207 mainly associated with environmental traits, we next interrogated whether there is genetic
208 contribution behind these epigenetic changes, and how genetics contribute to the DNA
209 methylation modules. In this sense, DNA methylation heritability was calculated for each CpG in

210 the modules. Two independent methods showed high agreement in heritability calculation
211 (Supplementary Figure 6A), so for the subsequent analysis variance decomposition model was
212 selected. Genetic contribution to methylation variability was shown to contribute differentially
213 between modules, being larger in S.Ho and S.He than in M.Ho and M.He modules (Figure 4A). This
214 is in agreement with the higher environmental contribution to M.He shown by EWAS traits
215 enrichments. Additionally, covariates as SARS-CoV-2 infection, age and gender were shown not to
216 modify the genetic contribution to DNA methylation changes (Supplementary Figure 6B). S.Ho and
217 S.He modules were the most affected by SARS-CoV-2 infection, while M.Ho and M.He variation
218 might be driven by other covariates or environmental factors that, unfortunately, were not
219 recorded in these cohorts (Supplementary Figure 6C).

220 In order to further investigate the genetic contribution to the DNA methylation changes observed
221 during COVID-19 progression, *cis*-mQTLs (methylation quantitative trait loci) were assessed
222 (significant results can be consulted in Supplementary Files). Linear regression models were fit
223 independently for each severity group (FDR < 0.05 for at least one group), showing that around
224 50% of the CpGs in each module were associated with at least one SNP (Supplementary Figure 6D).
225 In total, 7899 unique mQTLs were found to be significant for at least one of the severity groups,
226 composed of 7548 SNPs and 175 CpGs (out of 352 DMCs) with an average of 45 ± 84 SNPs by CpG,
227 what indicates that almost half of the DNA methylation changes found are being regulated by
228 large blocks of SNPs in *cis*. mQTLs were classified according to the SNP-CpG association
229 significance by severity groups, then labeling for example: a mQTL as mild specific, when the
230 significant association (p -value < 0.05) was only found in COVID-19 mild cases, or positive specific,
231 when both mild and severe cases showed a significant association (Figure 4B). mQTLs classification
232 showed a differential genetic regulation by module (Figure 4C), where methylation changes, which
233 follows COVID-19 progression (S.Ho and S.He modules), were enriched in mQTLs shared by all the

234 severity groups (common mQTLs), which means that the genetic regulation of these DNA
235 methylation changes does not depend on the severity of the disease but are a general regulatory
236 mechanism. On the other hand, mQTLs in M.Ho and M.He modules were mostly identified as
237 group-specific mQTLs, with a large fraction of mild and positive specific in M.He module, and mild,
238 severe and severe/negative specific in M.Ho module. The genetic regulation specificity of M.He is
239 also supported by significant differences of the normalized MAF (each group minor allele
240 frequency divided by all groups' minor allele frequency) for the mild and positive specific mQTLs
241 (Figure 4D). MAF in positive specific mQTLs showed a higher frequency in mild and severe groups
242 compared to negative individuals, while the mild specific mQTLs showed a higher MAF in mild
243 cases. Surprisingly, MAF differences were found between mild compared to severe and negative
244 individuals for common and positive specific mQTLs in S.Ho modules, which might indicate a
245 differential genetic regulation also for mild individuals for the S.Ho signature (Figure 4D).

246 The enrichment of the significant mQTLs by module were tested for SNPs previously known to be
247 associated with different traits. In this sense, mQTLs trait enrichments were performed
248 considering the *GWAS catalog database*²¹ and the COVID-19 associated SNPs from the COVID-19
249 Host Genetics Initiative^{5,22}. The results showed a strong enrichment of SNPs associated with
250 COVID-19 and interferon related autoimmune diseases (Systemic Lupus Erythematosus) in the
251 mQTLs regulating the S.Ho module and SNPs associated with non-interferon related autoimmune
252 diseases in the S.He module (Figure 4E). On the other hand, M.He mQTLs were enriched with
253 environmental related SNPs (Figure 4E), mimicking the enrichments shown above for the EWAS
254 catalog. Interestingly, two different COVID-19 GWAS regions are regulating the S.Ho and S.He
255 modules. In the case of the S.Ho module, its *cis*-mQTLs are composed of SNPs at 3p21.31 GWAS
256 peak^{22,23}, found to be associated in severe, hospitalized and in general SARS-CoV-2 lab positive
257 tested patients compared with the general population. While S.He module is enriched in SNPs

258 located at 8q24.13 GWAS peak ²², only found to be statistically significant in hospitalized COVID-19
259 patients compared to general population ²².

260 Discussion

261 The EWAS of SARS-CoV-2 infection reveals a DNA methylation regulation of important functional
262 pathways related with COVID-19 progression and specific epigenetic differences between severe
263 and mild patients. Differentially methylated CpG sites were shared between severe and mild cases,
264 mainly associated with the activation of interferon signaling pathway and the hyper-activation of B
265 and T lymphocytes. These pathways have been previously associated with COVID-19 severity in
266 transcriptome studies ^{10,24}, showing in this study that the regulation of these pathways is being
267 mediated by epigenetic changes at the promoter level of the implicated genes (Figure 1).

268 Apart from the DMCs shared between the differential analyses, the pathways enrichment analysis
269 for the individual regression models showed the epigenetic deregulation of specific pathways as
270 CD209 signaling (DC-SIGN), FCGR phagocytosis pathway and AKT signaling in specific blood cell-
271 types (Figure 2). CD209 is primarily expressed in dendritic cells and B-lymphocytes, and its
272 interaction with CD209L, expressed in SARS-CoV-2 target tissue endothelial cells, has been shown
273 to facilitate the virus entry ²⁵. Thus, CD209 signaling hypermethylation might be playing a
274 protective role during SARS-CoV-2 infection. Additionally, CD209 activation has been shown to
275 promote B-lymphocyte survival ²⁶. However, this process does not seem to be occurring in SARS-
276 CoV-2 infection as shown by the B-lymphocyte depletion observed in the deconvolution analysis
277 (Figure 1A). FCGR phagocytosis pathway is involved in the antibody-antigen complex clearance and
278 the antibody dependent cellular mediated cytotoxicity. CD8+ T-lymphocytes expressing FCGR3A
279 (CD16) have been described to acquire natural killer (NK) cell-like functional properties, thus
280 contributing to their cytotoxic functionality, increased in chronic hepatitis C virus infections ²⁷.

281 Recently, suppression of cytotoxic activity has been described on CD8+ T-lymphocytes and NK-cells
282 from severe COVID-19 patients ²⁸, which in the light of our DNA methylation results might be
283 impaired because of the DNA hypermethylation of genes of the FCGR3A phagocytosis pathway.
284 Based on our results, these two pathways seem to be associated with the progression of the
285 disease, showing significant DNA methylation changes along its course. On the other hand, gene
286 promoters related with the AKT signaling pathway were specifically found to be differentially
287 methylated when compared severe and mild cases (hypomethylated in mild), thus differentiating
288 at the epigenome level severe from mild SARS-CoV-2 infected patients. AKT signaling in CD8+ T-
289 lymphocytes is critical for the effector-memory transition of this cell-type ²⁹, thus impairing the
290 protective immune secondary response and potentially contributing to the worst outcome. Other
291 important genes, not annotated in these pathways, were found to show methylation differences,
292 as for example EDC3. Interestingly, hypermethylation of EDC3 in severe cases might be mediating
293 the overexpression of ACE2 protein in SARS-CoV-2 patients, thus favoring infection ³. EDC3 is a
294 component of a decapping complex that promotes removal of the monomethylguanosine (m7G)
295 cap from mRNAs, being an important protein during mRNA degradation, and its interaction with
296 ACE2 has been experimentally validated and shown with STRING interaction network ³⁰.

297 In addition to the COVID-19 EWAS results, DMCs were grouped by hierarchical clustering and
298 filtered by cohorts' similarity (Figure 3). Four modules of co-regulated CpGs were found, where
299 three of them are enriched in the functional pathways previously described. CD209 and FCGR
300 phagocytosis pathways (S.He module) are hypermethylated with the severity of the disease, and
301 both severe and mild cases, perfectly correlate with DNA methylation changes observed in SADs.
302 Hypomethylation along COVID-19 severity module (S.Ho) was found to be composed by two
303 signatures, an interferon related signature which correlates with interferon related systemic
304 autoimmune diseases (as MCTD, SLE or pSjS) at both severe and mild cases, and a T and B

305 lymphocyte activation signature, which correlates mainly with non-interferon related SADs (RA
306 and SSc) for severe cases. The AKT signaling pathway was also represented in the mild
307 hypomethylated module (M.Ho). The fourth module, hypermethylated in mild cases (M.He), is of
308 particular interest. It perfectly discriminates between severe and mild COVID-19 cases, and severe
309 DNA methylation changes are highly correlated with autoimmune conditions. Additionally, and in
310 contrast to the other CpG modules, its CpGs have not been related with autoimmune conditions
311 but with respiratory environmental conditions. Further analyses on this module revealed an
312 enrichment in CEBP binding sites (Supplementary Figure 6C). CEBP transcription factor has an
313 important role regulating IL-6 and IL-1 expression, whose elevated levels have been associated
314 with severe complications of COVID-19 disease ⁴. This result shows a reduced activity of CEBP
315 binding sites in mild cases compared with the severe ones, in a module where DMCs are enriched
316 in respiratory environmental traits. Altogether, our results suggest the existence of a relationship
317 between environmental exposure and the cytokine storm associated with the most critical
318 outcomes of COVID-19 disease.

319 The genetic regulation of COVID19 associated DNA methylation changes were also studied, finding
320 important differences between modules (Figure 4). In addition to a lesser genetic contribution to
321 the DNA methylation changes in M.Ho and M.He modules, the mQTLs associated to these modules
322 showed more group specificity than S.Ho and S.He modules. Importantly, *GWAS catalog*
323 enrichments for the mQTLs showed again a predominance of environmental traits related SNPs for
324 the M.He module, which reinforces the idea of the importance of the environmental exposure
325 during the regulation of the DNA methylation changes in this module.

326 This study is the first in depth large EWAS comparing SARS-CoV-2 RT-PCR positive and negative
327 individuals. The results show a large epigenetic regulation of autoimmune related functional
328 pathways during COVID-19 progression that differentiate severe from mild COVID-19 cases. Some

329 of these autoimmune related pathways presented DNA methylation differences between severe
330 and mild cases with less genetic contribution, but with higher genetic specificity than changes that
331 progress with the severity of the disease. Interestingly, these specific epigenetic changes were
332 mainly related, in terms of DNA methylation sites and SNPs regulating these sites, with
333 environmental traits. Thus, in the light of the results, the interaction between specific genetic
334 changes and different environmental exposure or life habits might be deregulating, via DNA
335 methylation changes, autoimmune related functional pathways which are related with the
336 worsening of SARS-CoV-2 infection. Despite the relationship between environmental exposure and
337 COVID-19 severity has been suggested in previous epidemiological studies, this is the first time
338 that this relationship is supported by genetic and epigenetic molecular information, thus,
339 contributing to the understanding of the disease at the molecular level. Of special importance is
340 the association of these environmental related DNA methylation changes with the cytokine storm
341 typical of the most severe COVID-19 cases.

342 Methods

343 Study design and cohorts

344 Whole blood samples from SARS-CoV-2 RT-PCR negative (101) and positive lab tested individuals
345 (473) were obtained from two clinical centers (*Hospital Clínico Universitario de Valladolid*,
346 discovery cohort and *Hospital Regional Universitario de Málaga*, validation cohort). The regional
347 ethical committees from Andalucía (*Comité Coordinador de Ética de la Investigación Biomédica de*
348 *Andalucía*) and from Valladolid (*COMITÉ DE ÉTICA DE LA INVESTIGACIÓN CON MEDICAMENTOS*
349 *ÁREA DE SALUD VALLADOLID*) approved the protocols and gave their ethical approval for this
350 study and all recruited individuals signed the informed consent prior to recruitment. Whole blood
351 was sampled upon arrival to the emergency ward, within a week after first symptoms. Discovery

352 and validation cohorts were recruited between March-April 2020 and August-October 2020,
353 respectively. Positive individuals were divided into: severe (WHO 5-7), if they needed invasive
354 respiratory support, ICU admission and/or died due to SARS-CoV-2 complications, and mild (WHO
355 2-4), if patients did not develop severe COVID-19 related symptoms. Severity groups between
356 cohorts were gender balanced, but slightly significant differences were found in terms of age
357 (Table 1).

358 Genomic Analysis

359 *DNA extraction*

360 DNA was extracted from whole blood samples by means of the *QIAamp DNA Blood Mini* kit and
361 the automatic platform *QIAcube Connect*. Afterwards, DNA quality was validated and normalized
362 using the *NanoDrop 2000c* and the *Qubit4*.

363 *Genotyping*

364 DNA was normalized to 200-400ng and genotyped with *Illumina's Infinium GSA-24.v3.0 BeadChip*,
365 following manufacturer's recommendations. Markers with genotyping rate > 99%, minor allele
366 frequency > 1% and a *p*-value for Hardy-Weinberg Equilibrium > 1e-6 were selected. Samples
367 showing genotyping rate < 98%, inconsistencies between reported and genetic sex and extreme
368 heterozygosity values ($-0.2 < F_{het} < 0.2$) were eliminated. The kinship coefficient was calculated
369 for each pair of samples and one member of each pair with a value ≥ 0.2 was removed. Based on
370 a set of Ancestry Informative Markers (markers which maximize the allelic frequencies across
371 1000Genomes populations), individuals with non-European ancestry components were
372 eliminated. The resulting dataset from this quality control process was imputed in the Michigan
373 Imputation Server³¹, using Minimac4 and 1000Genomes as reference panel³². After subsequent
374 filtering of the imputation result we obtained a working dataset consisting of 504 samples and

375 more than 9.5 million markers. Quality control of the genotyped data was performed with *Plink2.0*
376 ³³.

377 *Methylome profiling*

378 DNA methylation information was profiled with the *Illumina's Infinium MethylationEPIC BeadChip*,
379 after sample normalization to 500ng and bisulfite conversion with *EZ-96 DNA Methylation Kit*, as
380 recommended by the manufacturer. Methylomes were quality controlled by genotype
381 concordance (≥ 0.8) using shared SNP probes between platforms (genotypes were extracted after
382 imputation but without post filtering), gender prediction agreement (outliers > 5 standard
383 deviations), signal from noise detection p -value < 0.1 and minimum number of beads (>3) that
384 passed the detection p -value, the last two criteria were applied for both probes and samples.
385 Additionally, sexual chromosomes, cross-reactive probes and probes with overlapping SNPs from
386 *dbSNP v.147* ³⁴ were discarded. Methylation beta values were normalized by means of functional
387 normalization. After quality control, 574 samples and 768,067 probes were selected. The entire
388 process was performed with *minfi* and *meffil* R packages ^{35,36}.

389 Statistical Analysis

390 *Deconvolution of cell proportions*

391 Iterative hierarchical procedure implemented in *EpiDISH* R package ³⁷ was used to estimate the
392 main blood cell type proportions from methylome information with the robust partial correlation
393 method ³⁸. Whole blood cell type reference panel includes: neutrophils, monocytes, B-
394 lymphocytes, CD4+ T-Lymphocytes, CD8+ T-Lymphocytes and natural killer cells.

395 *Differential and interaction analysis*

396 Differential methylation analyses were performed by linear regression models, including gender,
397 sex and deconvoluted cell-proportions as covariates. Linear regression models including

398 interaction terms between the groups of interest and deconvoluted cell proportions, were used to
399 estimate the specific cell type(s) where the methylation changes occur, as proposed by Zheng et al
400 ³⁹. Methylation changes and interactions were considered significant at nominal p -values below
401 0.01 in discovery and validation datasets, and below a genome wide significant level of $5e-8$ in the
402 meta-analysis of both cohorts. Meta-analyses were performed with the restricted maximum
403 likelihood (REML) method and fixed effects implemented in *metafor R package* ⁴⁰.

404 *Enrichment, correlation and co-localization analysis*

405 DMCs (Differentially methylated CpGs) and/or genes that co-localized with them, based on the
406 Illumina annotation (*ilm10b4.hg19 R package*), were analyzed. Functional pathway analysis were
407 performed against *Reactome Pathway Database* ⁴¹ using *ReactomePA R package* ⁴². EWAS trait
408 enrichments were tested within the *EWAS Atlas* database ¹⁵. PRECISEADS methylomes ¹⁹ from
409 seven SADs (SLE, systemic lupus erythematosus; RA, rheumatoid arthritis; pSjS, primary Sjögren's
410 syndrome; SSc, systemic sclerosis; MCTD, mixed connective tissue disease; PAPS, primary anti-
411 phospholipids syndrome and UCTD, undifferentiated connective tissue disease) and healthy
412 controls were used to compare with COVID-19 epigenetic changes. TFBS (transcription factor
413 binding site) motif enrichment analysis was performed with *HOMER software* ⁴³ using a size of 200
414 nucleotides and including as background the CpGs interrogated with the EPIC array.

415 *Molecular pathway activity analysis*

416 Single-cell RNA-Seq datasets were obtained from *Schulte-Schrepping et al.* ¹⁷ (BD Rhapsody system
417 dataset, including neutrophils) and *Ren et al.* ¹⁶ (10x Genomics chromium dataset, not including
418 neutrophils). Cells from both datasets were selected based on: mitochondrial read percentage <
419 5%, hemoglobin read percentage < 1%, number of reads > 500 and < 6000, and number of genes
420 profiled between 200 and 2000. After the quality criteria filtering, almost all non-neutrophil cells

421 were lost from *Schulte-Schrepping et al.* dataset. Thus, CD8+ T-lymphocytes and B-lymphocytes
422 were analyzed from the Ren *et al.* dataset and neutrophils from the *Schulte-Schrepping et al.*
423 Individuals were classified as early or late based on *Schulte-Schrepping et al.* definition (late,
424 sampling >11 days after first symptoms) and authors 'defined cell-type annotation was used to
425 select two subsamples of 2500 cells for each cell-type (500 cells per severity group and onset
426 category). Molecular pathway activity values were estimated by means of *ssgsea* algorithm
427 implemented in *escape R package* ⁴⁴. HLA and Immunoglobulin genes were removed from the
428 *Reactome* pathways before activity calculation.

429 *Genetic statistical analyses*

430 Overall genetic contribution to DNA methylation changes (heritability, h^2) was estimated by
431 means of two models: one based on variance decomposition analysis from a linear mixed-model ⁴⁵
432 and the other one using the diagonalization trick ⁴⁶. The kinship matrix for the former model was
433 calculated by means of *popkin R package* ⁴⁷, while for the diagonalization trick estimation, *gaston*
434 *R package* recommendations were followed ⁴⁶. Methylation quantitative trait loci (mQTLs)
435 analyses were performed using the *matrix-eQTL R package* ⁴⁸. We applied a linear regression
436 model that tests the additive effects of allele dosages for each genetic variant on the DNA
437 methylation levels, while correcting for age, sex, the deconvoluted cell proportions and the first
438 two genetic principal components. We restricted analysis to *cis*-mQTL mapping (maximum
439 distance between CpG and SNPs of 1Mb) and SNPs with minor allele frequencies (MAF) > 0.05. *cis*-
440 mQTL analyses were performed independently on the different severity groups, using a FDR < 0.05
441 as significance threshold. Significant mQTLs were classified as common or specific QTLs based on
442 whether the association nominal *p*-values were below 0.05 for all the severity groups or not. Then
443 classifying non-common QTLs based on the severity groups that pass the threshold (QTL effects
444 were taken into consideration what might result on shared significant QTLs between groups but

445 with opposite effects). mQTLs enrichments were tested against SNP associated traits from the
446 GWAS catalog database ²¹ expanded with COVID-19 Host Genetics Initiative results ^{5,22}. GWAS
447 catalog traits were selected based on studies with a replication cohort and at least 50 SNPs below
448 the genomic significant threshold (p -value < 5e-8). Traits annotation into mQTLs were performed
449 based on linkage-disequilibrium blocks by means of *PLINK1.9 software* ^{33,49}, applying *blocks*
450 function ⁵⁰ default parameters in a maximum window size of 1MB.

451 Data availability

452 Genotypes summary statistics can be accessed through COVID-19 Host Genetic Initiative web page
453 (<https://www.covid19hg.org/>), included in project “*Determining the Molecular Pathways and*
454 *Genetic Predisposition of the Acute Inflammatory Process Caused by SARS-CoV-2 (SPGRX)*”.
455 Methylation data are available from Gene Expression Omnibus (GEO) at XXXXXXXX.

456 References

- 457 1 Guan, W. J. *et al.* Clinical Characteristics of Coronavirus Disease 2019 in China.
458 *The New England journal of medicine* **382**, 1708-1720,
459 doi:10.1056/NEJMoa2002032 (2020).
- 460 2 Huang, C. *et al.* Clinical features of patients infected with 2019 novel coronavirus in
461 Wuhan, China. *Lancet* **395**, 497-506, doi:10.1016/S0140-6736(20)30183-5 (2020).
- 462 3 Hoffmann, M. *et al.* SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2
463 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell* **181**, 271-280 e278,
464 doi:10.1016/j.cell.2020.02.052 (2020).
- 465 4 Del Valle, D. M. *et al.* An inflammatory cytokine signature predicts COVID-19
466 severity and survival. *Nature medicine* **26**, 1636-1643, doi:10.1038/s41591-020-
467 1051-9 (2020).
- 468 5 Initiative, C.-H. G. The COVID-19 Host Genetics Initiative, a global initiative to
469 elucidate the role of host genetic factors in susceptibility and severity of the SARS-
470 CoV-2 virus pandemic. *European journal of human genetics : EJHG* **28**, 715-718,
471 doi:10.1038/s41431-020-0636-6 (2020).
- 472 6 Harrison, S. L., Fazio-Eynullayeva, E., Lane, D. A., Underhill, P. & Lip, G. Y. H.
473 Comorbidities associated with mortality in 31,461 adults with COVID-19 in the
474 United States: A federated electronic medical record analysis. *PLoS medicine* **17**,
475 e1003321, doi:10.1371/journal.pmed.1003321 (2020).
- 476 7 Booth, A. *et al.* Population risk factors for severe disease and mortality in COVID-
477 19: A global systematic review and meta-analysis. *PloS one* **16**, e0247461,
478 doi:10.1371/journal.pone.0247461 (2021).

- 479 8 Rossen, L. M., Branum, A. M., Ahmad, F. B., Sutton, P. & Anderson, R. N. Excess
480 Deaths Associated with COVID-19, by Age and Race and Ethnicity - United States,
481 January 26-October 3, 2020. *MMWR. Morbidity and mortality weekly report* **69**,
482 1522-1527, doi:10.15585/mmwr.mm6942e2 (2020).
- 483 9 Li, X. *et al.* Clinical determinants of the severity of COVID-19: A systematic
484 review and meta-analysis. *PloS one* **16**, e0250602,
485 doi:10.1371/journal.pone.0250602 (2021).
- 486 10 Lucas, C. *et al.* Longitudinal analyses reveal immunological misfiring in severe
487 COVID-19. *Nature* **584**, 463-469, doi:10.1038/s41586-020-2588-y (2020).
- 488 11 Szklarczyk, D. *et al.* STRING v11: protein-protein association networks with
489 increased coverage, supporting functional discovery in genome-wide experimental
490 datasets. *Nucleic acids research* **47**, D607-D613, doi:10.1093/nar/gky1131 (2019).
- 491 12 Ziller, M. J. *et al.* Charting a dynamic DNA methylation landscape of the human
492 genome. *Nature* **500**, 477-481, doi:10.1038/nature12433 (2013).
- 493 13 Martino, D. & Saffery, R. Characteristics of DNA methylation and gene expression
494 in regulatory features on the Infinium 450k Beadchip. *bioRxiv*, 032862,
495 doi:10.1101/032862 (2015).
- 496 14 Hadjadj, J. *et al.* Impaired type I interferon activity and inflammatory responses in
497 severe COVID-19 patients. *Science* **369**, 718-724, doi:10.1126/science.abc6027
498 (2020).
- 499 15 Li, M. *et al.* EWAS Atlas: a curated knowledgebase of epigenome-wide association
500 studies. *Nucleic acids research* **47**, D983-D988, doi:10.1093/nar/gky1027 (2019).
- 501 16 Ren, X. *et al.* COVID-19 immune features revealed by a large-scale single-cell
502 transcriptome atlas. *Cell* **184**, 1895-1913 e1819, doi:10.1016/j.cell.2021.01.053
503 (2021).
- 504 17 Schulte-Schrepping, J. *et al.* Severe COVID-19 Is Marked by a Dysregulated
505 Myeloid Cell Compartment. *Cell* **182**, 1419-1440 e1423,
506 doi:10.1016/j.cell.2020.08.001 (2020).
- 507 18 Matsusaka, T. *et al.* Transcription factors NF-IL6 and NF-kappa B synergistically
508 activate transcription of the inflammatory cytokines, interleukin 6 and interleukin 8.
509 *Proceedings of the National Academy of Sciences of the United States of America*
510 **90**, 10193-10197, doi:10.1073/pnas.90.21.10193 (1993).
- 511 19 Barturen, G. *et al.* Integrative Analysis Reveals a Molecular Stratification of
512 Systemic Autoimmune Diseases. *Arthritis & rheumatology*, doi:10.1002/art.41610
513 (2020).
- 514 20 Muskardin, T. L. W. & Niewold, T. B. Type I interferon in rheumatic diseases.
515 *Nature reviews. Rheumatology* **14**, 214-228, doi:10.1038/nrrheum.2018.31 (2018).
- 516 21 Buniello, A. *et al.* The NHGRI-EBI GWAS Catalog of published genome-wide
517 association studies, targeted arrays and summary statistics 2019. *Nucleic acids*
518 *research* **47**, D1005-D1012, doi:10.1093/nar/gky1120 (2019).
- 519 22 Ganna, A. Mapping the human genetic architecture of COVID-19 by worldwide
520 meta-analysis. *medRxiv*, 2021.2003.2010.21252820,
521 doi:10.1101/2021.03.10.21252820 (2021).
- 522 23 Ellinghaus, D. *et al.* The ABO blood group locus and a chromosome 3 gene cluster
523 associate with SARS-CoV-2 respiratory failure in an Italian-Spanish genome-wide
524 association analysis. *medRxiv*, 2020.2005.2031.20114991,
525 doi:10.1101/2020.05.31.20114991 (2020).

- 526 24 Chen, Z. & John Wherry, E. T cell responses in patients with COVID-19. *Nature*
527 *reviews. Immunology* **20**, 529-536, doi:10.1038/s41577-020-0402-6 (2020).
- 528 25 Amraie, R. *et al.* CD209L/L-SIGN and CD209/DC-SIGN act as receptors for
529 SARS-CoV-2 and are differentially expressed in lung and kidney epithelial and
530 endothelial cells. *bioRxiv*, doi:10.1101/2020.06.22.165803 (2020).
- 531 26 Valentin, A. J. & Díaz, G. Y. CD209 activation promotes survival of lymphoblastic
532 human B cells. *The Journal of Immunology* **202**, 123.125-123.125 (2019).
- 533 27 Bjorkstrom, N. K. *et al.* Elevated numbers of Fc gamma RIIIA+ (CD16+) effector
534 CD8 T cells with NK cell-like function in chronic hepatitis C virus infection.
535 *Journal of immunology* **181**, 4219-4228, doi:10.4049/jimmunol.181.6.4219 (2008).
- 536 28 Yao, C. *et al.* Cell-Type-Specific Immune Dysregulation in Severely Ill COVID-19
537 Patients. *Cell reports* **34**, 108590, doi:10.1016/j.celrep.2020.108590 (2021).
- 538 29 Rogel, A. *et al.* Akt signaling is critical for memory CD8(+) T-cell development
539 and tumor immune surveillance. *Proceedings of the National Academy of Sciences*
540 *of the United States of America* **114**, E1178-E1187, doi:10.1073/pnas.1611299114
541 (2017).
- 542 30 Szklarczyk, D. *et al.* STRING v10: protein-protein interaction networks, integrated
543 over the tree of life. *Nucleic acids research* **43**, D447-452, doi:10.1093/nar/gku1003
544 (2015).
- 545 31 Das, S. *et al.* Next-generation genotype imputation service and methods. *Nature*
546 *genetics* **48**, 1284-1287, doi:10.1038/ng.3656 (2016).
- 547 32 Genomes Project, C. *et al.* A global reference for human genetic variation. *Nature*
548 **526**, 68-74, doi:10.1038/nature15393 (2015).
- 549 33 Chang, C. C. *et al.* Second-generation PLINK: rising to the challenge of larger and
550 richer datasets. *GigaScience* **4**, 7, doi:10.1186/s13742-015-0047-8 (2015).
- 551 34 Sherry, S. T., Ward, M. & Sirotkin, K. dbSNP-database for single nucleotide
552 polymorphisms and other classes of minor genetic variation. *Genome research* **9**,
553 677-679 (1999).
- 554 35 Fortin, J. P., Triche, T. J., Jr. & Hansen, K. D. Preprocessing, normalization and
555 integration of the Illumina HumanMethylationEPIC array with minfi.
556 *Bioinformatics* **33**, 558-560, doi:10.1093/bioinformatics/btw691 (2017).
- 557 36 Min, J. L., Hemani, G., Davey Smith, G., Relton, C. & Suderman, M. Meffil:
558 efficient normalization and analysis of very large DNA methylation datasets.
559 *Bioinformatics* **34**, 3983-3989, doi:10.1093/bioinformatics/bty476 (2018).
- 560 37 Zheng, S. C. *et al.* EpiDISH web server: Epigenetic Dissection of Intra-Sample-
561 Heterogeneity with online GUI. *Bioinformatics*, doi:10.1093/bioinformatics/btz833
562 (2019).
- 563 38 Teschendorff, A. E., Breeze, C. E., Zheng, S. C. & Beck, S. A comparison of
564 reference-based algorithms for correcting cell-type heterogeneity in Epigenome-
565 Wide Association Studies. *BMC bioinformatics* **18**, 105, doi:10.1186/s12859-017-
566 1511-5 (2017).
- 567 39 Zheng, S. C., Breeze, C. E., Beck, S. & Teschendorff, A. E. Identification of
568 differentially methylated cell types in epigenome-wide association studies. *Nature*
569 *methods* **15**, 1059-1066, doi:10.1038/s41592-018-0213-x (2018).
- 570 40 Viechtbauer, W. Conducting Meta-Analyses in R with the metafor Package. *Journal*
571 *of Statistical Software; Vol 1, Issue 3 (2010)* (2010).

- 572 41 Jassal, B. *et al.* The reactome pathway knowledgebase. *Nucleic acids research* **48**,
573 D498-D503, doi:10.1093/nar/gkz1031 (2020).
- 574 42 Yu, G. & He, Q. Y. ReactomePA: an R/Bioconductor package for reactome
575 pathway analysis and visualization. *Molecular bioSystems* **12**, 477-479,
576 doi:10.1039/c5mb00663e (2016).
- 577 43 Heinz, S. *et al.* Simple combinations of lineage-determining transcription factors
578 prime cis-regulatory elements required for macrophage and B cell identities.
579 *Molecular cell* **38**, 576-589, doi:10.1016/j.molcel.2010.05.004 (2010).
- 580 44 Borchering, N. & Andrews, J. *escape: Easy single cell analysis platform for*
581 *enrichment*, (2021).
- 582 45 Ziyatdinov, A. *et al.* lme4qtl: linear mixed models with flexible covariance structure
583 for genetic studies of related individuals. *BMC bioinformatics* **19**, 68,
584 doi:10.1186/s12859-018-2057-x (2018).
- 585 46 Manipulation of genetic data (SNPs). Computation of GRM and dominance matrix,
586 LD, heritability with efficient algorithms for linear mixed model (AIREML). (46th
587 European Mathematical Genetics Meeting (EMGM) 2018, Cagliari, Italy, April 18-
588 20, 2018, 2018).
- 589 47 Ochoa, A. & Storey, J. D. Estimating FST and kinship for arbitrary population
590 structures. *PLoS genetics* **17**, e1009241, doi:10.1371/journal.pgen.1009241 (2021).
- 591 48 Shabalin, A. A. Matrix eQTL: ultra fast eQTL analysis via large matrix operations.
592 *Bioinformatics* **28**, 1353-1358, doi:10.1093/bioinformatics/bts163 (2012).
- 593 49 Purcell, S. *et al.* PLINK: a tool set for whole-genome association and population-
594 based linkage analyses. *American journal of human genetics* **81**, 559-575,
595 doi:10.1086/519795 (2007).
- 596 50 Gabriel, S. B. *et al.* The structure of haplotype blocks in the human genome.
597 *Science* **296**, 2225-2229, doi:10.1126/science.1069424 (2002).

598

599 Acknowledgements

600 This work has been supported through *Consejería de Transformación Económica, Industria,*
601 *Conocimiento y Universidades* of the regional government of Andalucía cofounded by the
602 European Union through European Regional Development Fund (FEDER, CV20-10150), *Consejo*
603 *Superior de Investigaciones científicas* (CSIC-COV19-016/202020E155) and Junta de Castilla y León
604 (*Proyectos COVID* 07.04.467B04.74011.0 and IBGM excellence programme CLU-2029-02). G.B. is
605 supported by the Instituto de Salud Carlos III (ISCIII, Spanish Health Ministry) through the Sara
606 Borrell subprogram (CD18/00153). The authors would like to particularly express their gratitude to
607 the patients, nurses and many others who helped directly or indirectly in the consecution of this
608 study.

609 Author information

610 Contributions

611 **MEAR and GB** designed the study; **SRR, BS and DB** recruited the patients, performed their clinical

612 assessment, and obtained the samples; **CAD** performed genotyping and DNA methylation

613 profiling; **MMB** performed genotype data curation, imputation and processing; **GB** performed DNA

614 methylation data curation and processing; **GB and EC** performed data analyses; **GB, EC, MMB and**

615 **MEAR** discussed and interpreted the results; and **GB and MEAR** wrote the entire manuscript. All

616 authors approved of the content of the manuscript.

617 Corresponding authors


618 Correspondence to Guillermo Barturen or Marta E. Alarcón Riquelme

619 Ethics declarations

620 Competing interests


621 The authors declare no competing interests.

622 Figures




623

624 **Figure 1: COVID19 severity correlates with an increase in blood neutrophil proportion and**
 625 **epigenetic changes in genes related with the innate immune response.** (A) Methylome
 626 deconvoluted blood cell proportions are plotted by cohort (left panel discovery, right panel
 627 validation) and severity group (blue, negative SARS-CoV2 lab tested individuals; yellow, positive
 628 individuals with mild symptoms and red, positive individuals with severe symptoms). Paired
 629 differences were assessed by means of linear regression analysis (age and gender were included as
 630 covariates) and significance values plotted by pairs (p -value < 0.05 , * p -value < 0.01 and ** p -value $<$
 631 $1e-5$). (B) Venn diagram with the number of significant shared DMCs across the differential
 632 analysis performed (the number of annotated genes are included in parentheses). (C) Combined
 633 manhattan plots are shown for the differential analysis that share DMCs, hypermethylated and
 634 hypomethylated DMCs are divided into upper and lower side of the manhattan plot respectively.
 635 Genes annotated for the shared DMCs are depicted, including, in parentheses their co-localization
 636 with the annotated gene (TSS, Transcription Start Site: Body, gene body). Severe vs negative
 637 (blue), mild vs negative (green), severe vs mild (yellow) and pseudotime longitudinal analysis (red).



638


639 **Figure 2: COVID19 DNA methylation changes regulate autoimmune related functional pathways**
 640 **and associate with environmental respiratory related traits.** (A) Top 10 significant reactome
 641 database pathways (p -value < 0.01) are shown by differential analysis. (B) Number of DMCs with
 642 significant interactions for each deconvoluted cell-type proportion (red, B-cells; blue, CD4+ T-cells;
 643 orange, CD8+ T-cells; purple, monocytes; blue, neutrophils and green, NK-cells) are split into
 644 hypermethylated (upper panels) and hypomethylated (lower panel) and divided into the
 645 differential analysis. (C) EWAS traits enrichments (p -value $< 1e-10$) for each differential analysis
 646 are shown (MethBank database).



647

648 **Figure 3: Epigenetic changes in CpGs associated with environmental respiratory traits**
649 **differentiate COVID19 progression and mild cases from autoimmune disorders.** (A) Hierarchical
650 clustering of methylation DMCs for both discovery and validation cohorts (Ward's hierarchical
651 agglomerative clustering with Pearson correlation as distance is used). Individual methylation
652 values are averaged by severity from severe cases (top), mild cases (middle) to negative lab tested
653 SARS-CoV2 (bottom). The annotations in the upper part of the plot refer to the analysis to which
654 each CpG is differentially methylated (black). Four CpG modules highly replicated between
655 cohorts, were selected from the hierarchical clustering: S.Ho (Hypomethylated with the severity),
656 S.He (Hypermethylated with the severity), M.Ho (Hypomethylated in mild compared with severe
657 patients) and M.He (Hypermethylated in mild compared with severe patients and healthy
658 controls). (B) Reactome significant pathways by CpG module (p -value < 0.01) are shown. (C)
659 MethBank EWAS trait enrichment by CpG module (p -value < 1e-10) are shown. (D) Significant
660 overrepresentation of transcription factor binding site prediction (HOMER, p -value < 0.001) is
661 depicted by CpG module. (E) Average log₂FC Pearson correlations between COVID19 severity
662 groups and seven different systemic autoimmune conditions (SLE, systemic lupus erythematosus;
663 RA, rheumatoid arthritis; pSjS, primary Sjögren's syndrome; SSc, systemic sclerosis; MCTD, mixed


664 connective tissue disease; PAPs, primary antiphospholipid syndrome and UCTD, undifferentiated
 665 connective tissue disease). DMCs are grouped by CpG modules.



666


667 **Figure 4: Genetics contributes differentially to progressive and mild specific DNA methylation**
 668 **changes.** (A) Genetic contribution in terms of the fraction of the variance explained (heritability,
 669 h^2) of individual CpG methylation changes is shown by DNA methylation module. Statistical
 670 differences are assessed by means of Wilcoxon test p -values. (B) Three significant mQTLs
 671 regulating DNA methylation levels are shown divided by severity group and genotype. From left to
 672 right, a common mQTL for all three severity groups in the S.Ho module, a positive specific mQTL
 673 and a mild specific mQTL for M.He module are depicted. (C) Fraction of mQTL categories are
 674 plotted by module and for all significant DMCs together. (D) Normalized MAFs for the largest
 675 mQTL categories (common mQTLs, positive specific mQTLs and mild specific mQTLs) represented
 676 in at least three modules (S.Ho, S.He and M.He) are shown divided by severity group. Wilcoxon
 677 test p -values were calculated between severity groups. (E) Enrichment of GWAS catalog and
 678 COVID-19 Host Genetics Initiative associated SNPs are shown by CpG module (p -value < 1e-10).

679 Supplementary Figures



680


681 **Supplementary Figure 1: Technical batch effect does not bias the methylation profiles.** t-SNE
 682 analysis of the 10,000 most variable CpGs (based on the DNA methylation absolute deviation
 683 mean) is shown colored by different variables: (A) severity groups, (B) neutrophil proportion, (C)
 684 cohorts and (D) technical batch.



685


686 **Supplementary Figure 2: Hypomethylated and hypermethylated DMCs are mostly enriched and**
 687 **colocalized with gene regulatory elements, which tend to activate and inactivate in *cis* gene**

688 **expression levels.** (A) Significant DMCs enrichment from each differential analysis across different
 689 regulatory elements (annotatr R package). Hypermethylated and hypomethylated DMCs are
 690 divided into left and right panels, respectively. Each DMC is allowed to be annotated in more than
 691 one of the following features: 1 to 5kb, region between 1-5kb upstream from the TSS; promoters,
 692 region at less than 1kb upstream, from the TSS; 5' UTR region; first exon; CDS, protein coding
 693 regions; exon; intron; exon-intron boundaries; intron-exon boundaries; 3' UTR region; intergenic,
 694 not colocalized with any gene annotation; CGI, CpG island; CGI shores, at less than 2kb of a CGI;
 695 CGI shelves, at 2-4kb of a CGI; interCGI, not colocalized with any CGI annotation; lncRNA genes,
 696 GENCODE long non-coding gene annotation and enhancer, colocalized with FANTOM5 enhancer
 697 database annotation. Enrichment score is defined as the log₂FC between the fraction of
 698 colocalized DMCs and the CpGs in the EPIC array. Significance was calculated by means of a Fisher
 699 exact test (p -value < 0.05, * p -value < 0.01 and ** p -value < 1e-5). (B) Fraction of colocalized DMCs
 700 by differential analysis for ranked gene features obtained from the EPIC array annotation (each
 701 DMC is assigned to one feature according to: TSS, transcriptions start site > 5' UTR > 3' UTR > Body,
 702 gene body not in the previous features > Intergenic, not assigned to any gene).




703

704 **Supplementary Figure 3: Interferon exhaustion in severe COVID-19 patients is not regulated by**
 705 **DNA methylation changes.** (A-F) DNA methylation z-scored levels for CpGs colocalized with
 706 interferon gene signature promoters are shown by COVID severity group in discovery and
 707 validation cohorts. Wilcoxon test p -values are depicted by pairs.




708

709 **Supplementary Figure 4: Enriched pathway activity in the CpG modules follow DNA methylation**
710 **changes at early SARS-CoV-2 samplings in the cell-types with significant interactions.** Reactome
711 CD209 signaling (A), interferon alpha/beta signaling (B), FCGR3A-mediated phagocytosis (C) and
712 PIP3 activates AKT signaling (D) activities were calculated per individual with *ssgsea* R package and
713 grouped by COVID-19 severity groups at early and late samplings (>11 days after first symptoms)
714 for B-cells, CD8+ T-cells and Neutrophils. Activities were plotted for two randomly selected subsets
715 of 2500 cells, 500 cells per group. Wilcoxon test *p*-values are depicted against healthy controls.



716

717 **Supplementary Figure 5: Progressive hypomethylation during COVID-19 severity CpG module**
 718 **(S.Ho) is composed of two different functional signatures.** (A) logFC correlation plots for severe
 719 and mild COVID-19 cases against two interferon related diseases (MCTD and pSjS) and two non-
 720 interferon related diseases (RA and SSc) are shown. Correlation coefficients and p -values are
 721 shown by pairs. (B) logFC correlation plots without strongest hypomethylated CpGs are shown.



722

723 **Supplementary Figure 6: Genetic and non-genetic DNA methylation explained variance analyses.**
 724 (A) Genetic heritability correlation between two independent methods is shown by CpG module
 725 (Linear mixed-model variance decomposition and Linear mixed-model fitting with the
 726 diagonalization trick were used). Correlation coefficients and p -values are depicted by module. (B)
 727 Genetic heritability correlation between linear mixed-model variance decomposition with and




728 without fixed effect covariates (SARS-CoV-2 infection, gender and age) is plotted. Correlation
729 coefficients and p -values are depicted by module. (C) Fraction of DNA methylation variance
730 explained by fixed effect covariates is shown for each CpG module. (D) Fraction of CpGs by module
731 associated with at least one SNP is shown.




732 Tables






| | Discovery (10 Technical Batches) | | | | | Validation (3 Technical Batches) | | | | |
|-----------------|-------------------------------------|----------|-----------|--------------|----------|-------------------------------------|----------|-----------|--------------|----------|
| | # | Age | Gender | Hospitalized | Deceased | # | Age | Gender | Hospitalized | Deceased |
| Negative | 47 | 63 ± 21 | 20 (43%) | - | - | 54 | 67 ± 20 | 27 (50%) | - | - |
| Mild | 269 | 67 ± 15* | 126 (47%) | 216 (80%)* | - | 91 | 61 ± 18* | 48 (53%) | 87 (96%)* | - |
| Severe | 98 | 76 ± 14* | 126 (47%) | 98 (100%) | 84 (86%) | 15 | 64 ± 18* | 126 (47%) | 15 (100%) | 10 (67%) |

733


734 **Table 1: Cohorts' demographic and clinical information.** Number of individuals (#), age average ± standard deviation
735 (Age), number and percentage of males (Gender), hospitalized individuals (Hospitalized) and deceased individuals
736 (Deceased) are shown by severity group and cohort. (*) Discovery and validation cohorts showed significant differences
737 in terms of age in mild and severe groups (Mann-Whitney U test p -value < 0.05) and also in terms of numbers of
738 hospitalized mild symptoms patients (Fisher exact test < p -value 0.05).









A




B




C







E




D







A



B




Colocalization annotations




Differential analysis




A




B




C





D



E




F




A

CD209 (DC-SIGN) signaling




B

Interferon alpha/beta signaling




C

FCGR3A-mediated phagocytosis




D

PIP3 activates AKT signaling



A


S.Ho modules correlations



MCTD vs Mild ($R = 0.45$, p -value = 0.0011)
 pSjS vs Mild ($R = 0.48$, p -value = 0.0005)
 RA vs Mild ($R = -0.07$, p -value = 0.62)
 SSc vs Mild ($R = -0.05$, p -value = 0.74)

MCTD vs Severe ($R = 0.31$, p -value = 0.032)
 pSjS vs Severe ($R = 0.32$, p -value = 0.023)
 RA vs Severe ($R = 0.47$, p -value = 0.0007)
 SSc vs Severe ($R = 0.41$, p -value = 0.004)

B

S.Ho module correlation
without strongest hypomethylated CpGs

MCTD vs Mild ($R = 0.1$, p -value = 0.54)
 pSjS vs Mild ($R = 0.22$, p -value = 0.19)
 RA vs Mild ($R = 0.0024$, p -value = 0.99)
 SSc vs Mild ($R = -0.097$, p -value = 0.57)

MCTD vs Severe ($R = 0.044$, p -value = 0.8)
 pSjS vs Severe ($R = 0.058$, p -value = 0.73)
 RA vs Severe ($R = 0.44$, p -value = 0.0059)
 SSc vs Severe ($R = 0.3$, p -value = 0.07)

